Key Insights

Highlights

Success Rate

81% trial completion

Published Results

62 trials with published results (21%)

Research Maturity

150 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

12.0%

35 terminated out of 292 trials

Success Rate

81.1%

-5.5% vs benchmark

Late-Stage Pipeline

17%

50 trials in Phase 3/4

Results Transparency

41%

62 of 150 completed with results

Key Signals

62 with results81% success35 terminated

Data Visualizations

Phase Distribution

230Total
Not Applicable (58)
Early P 1 (2)
P 1 (46)
P 2 (74)
P 3 (40)
P 4 (10)

Trial Status

Completed150
Unknown61
Terminated35
Recruiting19
Withdrawn12
Active Not Recruiting8

Trial Success Rate

81.1%

Benchmark: 86.6%

Based on 150 completed trials

Clinical Trials (292)

Showing 20 of 20 trials
NCT03812874Phase 1WithdrawnPrimary

A Study of PTX-9908 Injection for Non-resectable HCC With TACE

NCT07849660Active Not RecruitingPrimary

Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)

NCT03897543Phase 1CompletedPrimary

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

NCT05540925CompletedPrimary

Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma

NCT07227012Phase 1RecruitingPrimary

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

NCT06084234Phase 4RecruitingPrimary

National Liver Cancer Screening Trial

NCT05908786Phase 1TerminatedPrimary

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

NCT03878550Active Not RecruitingPrimary

Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

NCT04246177Phase 3TerminatedPrimary

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT07727759Recruiting

CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure

NCT07745153Completed

Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors

NCT07010497Phase 2RecruitingPrimary

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

NCT01171651Phase 2CompletedPrimary

A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

NCT04962958Phase 2Completed

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

NCT04102098Phase 3CompletedPrimary

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

NCT05486572Not ApplicableRecruitingPrimary

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

NCT00554372Phase 2CompletedPrimary

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

NCT03017326Phase 3Active Not Recruiting

Paediatric Hepatic International Tumour Trial

NCT06794073Not ApplicableRecruitingPrimary

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

NCT02366286Completed

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

Scroll to load more

Research Network

Activity Timeline